Why the study?
Uncertainty remains regarding the association between body mass index and bleeding risk in patients with non-valvular atrial fibrillation.
Is body mass index associated with the risk of bleeding in elderly patients with non-valvular atrial fibrillation taking dabigatran?
Population
509 elderly NVAF patients taking dabigatran at twelve centers in China
Comparison
Baseline BMI
Design
Multicenter cohort study
Follow-up
Six months
Key result
Every 1 kg/m2 increase in body mass index was associated with a 12% increased risk of bleeding (HR 1.12) in elderly patients with non-valvular atrial fibrillation treated with dabigatran.
Authors
Loading...
May warrant BMI-informed bleeding vigilance in elderly NVAF on dabigatran; leaves open causality and prospective validation.
Cohort (n=509)
Yes
Is body mass index associated with the risk of bleeding in elderly patients with non-valvular atrial fibrillation taking dabigatran?
Hazard Ratio: 1.12 (95% CI 1.02–1.24)
p-value: p=0.021
Higher body mass index is associated with an increased risk of bleeding in elderly patients with non-valvular atrial fibrillation treated with dabigatran.
Li et al. (2020) conducted a cohort in Non-valvular atrial fibrillation (n=509). Body mass index (BMI) vs. Lower BMI was evaluated on Bleeding events within six months (HR 1.12, 95% CI 1.02-1.24, p=0.021). Every 1 kg/m2 increase in body mass index was associated with a 12% increased risk of bleeding (HR 1.12) in elderly patients with non-valvular atrial fibrillation treated with dabigatran.